A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma

Table 3

Treatment-related adverse events of US FDA-approved PD-1/PD-L1 inhibitors in patients with urothelial carcinoma.

Target	Inhibitor name	Treatment-related adverse events	Immune-related adverse events
PD-1	Nivolumab	Fatigue, decreased appetite, nausea, musculoskeletal pain, diarrhea, rash	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction, encephalitis, rash
	Pembrolizumab	Fatigue, decreased appetite, nausea, musculoskeletal pain, diarrhea, rash, pruritus, constipation	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction
PD-L1	Atezolizumab	Fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, constipation	Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), meningitis/encephalitis, pancreatitis, dermatitis/rash
	Durvalumab	Fatigue, decreased appetite, nausea, urinary tract infection, diarrhea, musculoskeletal pain, constipation, peripheral edema	Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis
	Avelumab	Fatigue, decreased appetite, nausea, urinary tract infection, musculoskeletal pain	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction